Tempest Therapeutics (TPST) News Today $0.90 +0.03 (+3.45%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Research Analysts Issue Forecasts for TPST FY2024 EarningsNovember 19 at 1:17 AM | americanbankingnews.comHC Wainwright Has Optimistic Outlook of TPST FY2024 EarningsNovember 17, 2024 | americanbankingnews.comTempest Therapeutics (NASDAQ:TPST) Given "Buy" Rating at HC WainwrightNovember 15, 2024 | americanbankingnews.comTempest Therapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comTempest Therapeutics price target lowered to $5 from $8 at Piper SandlerNovember 13, 2024 | markets.businessinsider.comTempest Therapeutics: Promising Advancements and Strategic Partnerships Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comTempest Therapeutics: Tempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finanznachrichten.deTempest receives FDA study may proceed for Phase 3 trial of amezalpatNovember 13, 2024 | markets.businessinsider.comTempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finance.yahoo.comTempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comTempest Therpeutics options imply 22.5% move in share price post-earningsNovember 9, 2024 | markets.businessinsider.comTraders Digest Consumer Inflation Measure as US Equity Futures Drop Pre-BellOctober 12, 2024 | msn.comScotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)October 11, 2024 | markets.businessinsider.comTempest Agrees To Extend Limited Duration Stockholder Rights PlanOctober 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tempest Therapeutics Amid Positive Developments and Strategic Roche CollaborationOctober 10, 2024 | markets.businessinsider.comWhy Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?October 10, 2024 | finance.yahoo.comPerimeter Solutions (NYSE:PRM) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comTempest Inks Deal With Roche To Support Advancement Of Amezalpat Combination TherapyOctober 10, 2024 | markets.businessinsider.comTempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal TrialOctober 10, 2024 | globenewswire.comTempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 20, 2024 | globenewswire.comTempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory AffairsSeptember 18, 2024 | finance.yahoo.comTempest Flounders on News of Test ResultsSeptember 13, 2024 | msn.comTempest to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 23, 2024 | globenewswire.comTempest set to storm the HCC landscape with promising Phase II amezalpat dataAugust 21, 2024 | finance.yahoo.comTempest Announces the Appointment of Troy M. Wagner as Vice President of Quality AssuranceAugust 21, 2024 | finance.yahoo.comScotiabank maintains a target on Tempest Therapeutics stockAugust 18, 2024 | uk.investing.comBuy Rating Affirmed for Tempest Therapeutics Amidst Promising Phase 3 Outlook and Funding UncertaintiesAugust 15, 2024 | markets.businessinsider.comTempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular CarcinomaAugust 15, 2024 | globenewswire.comTempest Therapeutics, Inc. (NASDAQ:TPST) Major Shareholder Versant Venture Capital Vi, L. Sells 387,999 SharesAugust 13, 2024 | insidertrades.comBuy Rating Affirmed for Tempest Therapeutics Amid Strong Clinical Results and Solid FinancialsAugust 9, 2024 | markets.businessinsider.comTPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024August 9, 2024 | investorplace.comTempest Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), CVS Health (CVS) and Tempest Therapeutics (TPST)July 27, 2024 | markets.businessinsider.comTempest Therapeutics, Inc. (NASDAQ:TPST) CEO Purchases $73,850.00 in StockJuly 9, 2024 | insidertrades.comTempest Therapeutics, Inc. (NASDAQ:TPST) Insider Justin Trojanowski Purchases 7,500 SharesJuly 3, 2024 | insidertrades.comWhat's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?June 20, 2024 | benzinga.comWhy Is Tempest Therapeutics (TPST) Stock Up 45% Today?June 20, 2024 | investorplace.comTempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular CarcinomaJune 18, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2024 | globenewswire.comGlancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)May 31, 2024 | businesswire.comTempest to Participate in Upcoming Investor ConferencesMay 21, 2024 | finance.yahoo.comTempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Increase in Short InterestTempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 1,580,000 shares, a growth of 39.8% from the April 15th total of 1,130,000 shares. Based on an average daily trading volume, of 901,800 shares, the short-interest ratio is presently 1.8 days. Currently, 9.4% of the company's stock are sold short.May 12, 2024 | marketbeat.comBuy Rating Affirmed for Tempest Therapeutics Amidst Promising Clinical AdvancementsMay 10, 2024 | markets.businessinsider.comTempest Therapeutics: Tempest Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | finanznachrichten.deTPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024May 10, 2024 | markets.businessinsider.comTempest Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 26, 2024 | globenewswire.comTempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest UpdateTempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 969,700 shares, a growth of 26.5% from the March 15th total of 766,800 shares. Currently, 6.1% of the shares of the stock are short sold. Based on an average daily volume of 1,030,000 shares, the short-interest ratio is currently 0.9 days.April 13, 2024 | marketbeat.comTempest Therapeutics (NASDAQ:TPST) Trading Down 6.8%Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 6.8%April 13, 2024 | marketbeat.com Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin TPST Media Mentions By Week TPST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TPST News Sentiment▼-0.170.45▲Average Medical News Sentiment TPST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TPST Articles This Week▼101▲TPST Articles Average Week Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GNLX News ME News CASI News FBLG News PMVP News ONCY News IKNA News QNCX News CLSD News CMRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TPST) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
